Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Danaher Corp.

http://www.danaher.com

Latest From Danaher Corp.

Bespoke Gene Therapy ‘Playbook’ Outlines Platform Approach To AAV-Based Treatments

Supporting ‘n of 1’ gene therapy development, the playbook from a Foundation for the National Institutes of Health-backed consortium aims to help investigators who are not traditional product sponsors prepare for meetings with US FDA and IND submissions.

Gene Therapy Clinical Trials

The John Green Effect: Will Industry Be Influenced Again?

Drug and device makers regularly use media to sway consumers. But some advocacy groups recently turned the tables by using social media to sway industry. 

Business Strategies Commercial

MTI 100: Global Medtech Recovers Core Growth After A Year Like No Other

With many medtechs restructuring for core growth in the post-pandemic era, Abbott relied on organic growth in 2022 to move to the top of the global medtech ranking. The strength of the US dollar was not kind to companies reporting in local currencies on converting revenues to dollars.

Medtech 100 Commercial

Deals in Depth August 2023

In the top August alliance by deal value, Precision BioSciences licensed Imugene global rights to azercabtagene zapreleucel (azer-cel), its lead allogeneic anti-CD19 CAR T candidate for cancer. Imugene will assume ongoing clinical execution for azer-cel in the large B-cell lymphoma population who have relapsed following autologous CAR T treatment. The license also includes an option to develop up to three other cancer research programs in the future. Precision will receive $21m up front and is eligible for $8m upon successful completion of the Phase Ib dosing in the CAR T relapsed LBCL patient population. For azer-cel, Precision is eligible to receive up to $198m in additional milestone payments plus royalties. For each additional research program selected by Imugene, Precision is eligible for up to $145m in milestone payments and tiered royalties on net sales.

Deals Financing
See All

Company Information

  • Industry
  • In Vitro Diagnostics
  • Medical Devices
  • Research, Analytical Equipment & Supplies
  • Other Names / Subsidiaries
    • Beckman Coulter
    • Cepheid
    • Cytiva
    • GE Life Sciences
    • Hybritech
    • Pall Corporation
    • Radiometer Medical ApS
    • HemoCue AB
    • Integrated DNA Technologies, Inc.
    • Leica Microsystems Inc.
    • Leica Biosystems Inc.
    • Vision Systems Ltd.
    • Coretech Holdings, LLC
    • Q3DM Inc.
    • Aldevron LLC
UsernamePublicRestriction

Register